Stock AIM AIM IMMUNOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Market Closed - Nyse
Other stock markets
 16:00:00 2024-05-03 EDT 		5-day change 1st Jan Change
0.4048 USD +0.15% Intraday chart for AIM ImmunoTech Inc. -5.46% -7.98%
04-29 AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed MT
04-10 AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer CI

Evolution of the average Target Price on AIM ImmunoTech Inc.

Price target over the last 5 years

History of analyst recommendation changes

7885a6ec780c08fc44e0.M1gQjjNPu3jWQHyN81zU65_PSbH5uhYg8gPUmGjnS1k.XBxmxH5i7Cq6GEu7yjmsg-75A9C113FDlDHg1iCkZnR3GyXAXirjHYYyTA~b8d37cd2b2c083d66ed096c1dde6eeb4

Analyst Recommendations on AIM ImmunoTech Inc.

Maxim Group Adjusts AIM ImmunoTech Price Target to $3 From $5, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4048 USD
Average target price
3.5 USD
Spread / Average Target
+764.62%
High Price Target
5 USD
Spread / Highest target
+1,135.18%
Low Price Target
2 USD
Spread / Lowest Target
+394.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AIM ImmunoTech Inc.

Maxim

Ratings for AIM ImmunoTech Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AIM Stock
  4. Consensus AIM ImmunoTech Inc.